{"url_path":"/sec/supn/8-k/2026-05-20/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-20","source_url":"https://www.sec.gov/Archives/edgar/data/1356576/0001356576-26-000025-index.html","accession_number":"0001356576-26-000025","cik":"0001356576","ticker":"SUPN","issuer_name":"SUPERNUS PHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1356576/0001356576-26-000025-index.html","primary_entity_key":"0001356576","primary_entity_name":"SUPERNUS PHARMACEUTICALS, INC."},"word_count":122,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits\n\nExhibitDescription\n\n10.1*\n[Exhibit 10.1* - Contingent Value Rights Agreement, dated as of July 30, 2025, by and among Supernus Pharmaceuticals, Inc. and Equiniti Trust Company, LLC (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed on July 31, 2026, File No. 001-35518).](https://www.sec.gov/Archives/edgar/data/1356576/000110465925072506/tm2522014d3_ex10-1.htm)\n\n104The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.\n\n*Previously filed.\n\n2\n\nSIGNATURES\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. \n\n SUPERNUS PHARMACEUTICALS, INC.\n\n  \n\nDATED: May 20, 2026By:/s/ Timothy C. Dec\n\n  Timothy C. Dec\nSenior Vice President and Chief Financial Officer\n\n3"}